News Archive

GERMANTOWN, Md., Jan. 6, 2020 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PRGN-3006, a first-in-class investigational therapy using Precigen’s non-viral UltraCAR-T™ therapeutic platform for patients with relapsed or refractory acute myeloid leukemia (AML) (clinical trial identifier: NCT03927261). Precigen announced in Q3 2019 that it had completed enrollment for the first cohort of this clinical trial and expects an initial data readout in the second half of 2020.

Low-carb diet success story Sabrina Williams, above, who drastically reduced her weight from 257 pounds.

A new group called the Low-Carb Action Network (LCAN), a coalition of doctors, academics, and average Americans with personal success stories using low-carb diets, has launched to urge U.S. nutrition leaders to include a true low-carb diet as part of the 2020 Dietary Guidelines for Americans (DGA).

LCAN members point to a large and rapidly growing body of strong scientific research showing carbohydrate restriction to be a safe and effective strategy to prevent and even reverse chronic, diet-related conditions such as pre-diabetes/type 2 diabetes, overweight/obesity, and high blood pressure along with a broad array of other cardiovascular risk factors.

GAITHERSBURG, Md., Dec. 19, 2019 /PRNewswire/ — MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that Shruti Abbato has joined the Company as Executive Vice President, Business Development for CARMA Cellular Therapies. Ms. Abbato will lead development of new partnerships for the Company’s CARMA platform programmes. 

Significant strides have been made towards the management of pediatric cancers, yet we still come up short with delivering a cure for many of our littlest patients. Further, even when children achieve long-term survival, they can experience long-term adverse effects from the disease or treatment.

Johns Hopkins University will close its graduate programs in Rockville by the summer of 2020, dealing a blow to the county’s ambitions of expanding higher education opportunities.

The university plans to consolidate the Center for Biotechnology Education on Medical Center Drive with the program’s main campus in Baltimore, said Leslie Ford Weber, the director of campus, government and community affairs for Johns Hopkins in Montgomery County.

Image: https://bethesdamagazine.com

As president of the University of Maryland, Baltimore (UMB), Jay A. Perman, MD, has challenged the University to promote big ideas and be forward-looking. To celebrate his nearly 10-year tenure, however, a look backward was appropriate.

In that vein, nostalgia and sentiment filled the air Dec. 12 at the SMC Campus Center, where a crowd of about 400 packed the second-floor Elm Ballrooms to pay tribute to Perman, who will become the fifth chancellor of the University System of Maryland (USM) on Jan. 6.

Image: Dr. Perman greeted a line of well-wishers before and after the celebration on Dec. 12 at the SMC Campus Center. – https://www.umaryland.edu

Oxford, UK – 18 December 2019: Vaccitech Ltd announced today that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT), has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer (NSCLC).

Cancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer.

The vaccine treatment developed by VOLT, a strategic collaboration between Vaccitech Ltd and the Ludwig Institute for Cancer Research, is designed to stimulate the body’s immune system to attack cancer cells. It will deliver cancer-associated antigens (MAGE A3 and NY-ESO-1) to antigen presenting cells called dendritic cells, causing the immune system to produce cytotoxic T cells, which target and kill cancerous cells expressing the antigens.

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today an expansion of its facility in Frederick, Maryland for the second time in 2019. The addition of 5,000 square feet to its existing 15,500 footprint supports the company’s expansion efforts and provides infrastructure to meet a growing international demand for its standardized hMSC bioprocess tools. By strengthening its cell manufacturing solution portfolio and presence in the Asia Pacific and Europe, RoosterBio is giving more people around the world the ability to advance regenerative medicine cures.

Image: https://biobuzz.inloop.com

Do you want to work with cutting-edge technology in 3D Tissue Model space. Mimetas, the market leader in 3D platform technologies, is seeking a critical thinker to work in our Gaithersburg, MD location. This person will have opportunity to influence discovery in a variety of disease indications, including cancer, inflammation, and drug safety. See attached description for more details.